The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Improved Understanding of JAK2 Inhibition in Polycythemia Vera

John O. Mascarenhas, MD
Published Online: 10:59 PM, Wed November 8, 2017

John O. Mascarenhas, MD, associate professor of medicine, Icahn School of Medicine at Mount Sinai Hospital, discusses the optimal use of ruxolitinib (Jakafi) and the improved understanding of JAK2 inhibition of polycythemia vera.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.